Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies

Sponsored by UCB

Feb 19, 2025 11:00 am

(156.79 KB)

Presentation

Coates RNBL2025

Laura C. Coates, M.D.

Author(s):

Philip J. Mease,William Tillett, Maarten de Wit, Laure Gossec, M. Elaine Husni, Fabian Proft, Barbara Ink, Rajan Bajracharya, Jason Coarse, Jérémy Lambert, Laura C. Coates,Alice B. Gottlieb

Abstract or description:

This study aimed to report the impact of longer-term bimekizumab (BKZ) treatment up to 2 years on patient-reported pain and fatigue in patients with psoriatic arthritis (PsA) who were biologic disease-modifying antirheumatic drug (bDMARD)-naïve or had inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi-IR).

These studies were funded by UCB. All costs associated with development of this presentation were funded by UCB.

More Virtual Posters

Sanofi RNL Poster

Effectiveness of Interleukin-6 Receptor Inhibitors versus Conventional Synthetic Immunomodulatory Therapy for Treatment of Frail Patients with Polymyalgia Rheumatica

Avacopan Versus Prednisone Taper in Patients With ANCA-Associated Vasculitis Without Kidney Involvement in a Phase 3 Trial

Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies

Effectiveness of IL-6 Receptor Inhibitors versus Methotrexate or any Conventional Immunomodulators in Patients with Steroid Refractory Polymyalgia Rheumatica

Presentation

Coates RNBL2025

Laura C. Coates, M.D.

Author(s):

Philip J. Mease,William Tillett, Maarten de Wit, Laure Gossec, M. Elaine Husni, Fabian Proft, Barbara Ink, Rajan Bajracharya, Jason Coarse, Jérémy Lambert, Laura C. Coates,Alice B. Gottlieb

Abstract or description:

This study aimed to report the impact of longer-term bimekizumab (BKZ) treatment up to 2 years on patient-reported pain and fatigue in patients with psoriatic arthritis (PsA) who were biologic disease-modifying antirheumatic drug (bDMARD)-naïve or had inadequate response or intolerance to tumor necrosis factor inhibitors (TNFi-IR).

These studies were funded by UCB. All costs associated with development of this presentation were funded by UCB.

×